PISCES (2026) — Trial Summary
PISCES (2026): Double-blind, randomized, placebo-controlled trial at 26 sites in Canada and Australia assigning 1,228 adults on maintenance hemodialysis to daily fish oil (4 g n−3 polyunsaturated fatty acids: 1.6 g EPA + 0.8 g DHA) or corn-oil placebo (ISRCTN00691795). Primary end point: composite o
References
- Lok CE, Farkouh M, Hemmelgarn BR, et al; PISCES Investigators. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. N Engl J Med. 2026;394(2):128-137. ISRCTN00691795.